5. Stock-Based Compensation

The compensation costs that have been charged against income for the thirteen and thirty-nine weeks ended October 28, 2017 and October 29, 2016 were as follows (in thousands):

	Thirteen Weeks Ended				Thirty-Nine Weeks Ended
	October 28, 2017		October 29, 2016		October 28, 2017		October 29, 2016
Stock-based compensation expense by type:
Stock options	$	8	$	-	$	181	$	384
Restricted stock unit awards, including performance-based		796		629		2,905		3,237
Employee stock purchases		19		22		75		80
Director deferred compensation		6		24		18		70
Total stock-based compensation expense		829		675		3,179		3,771
Income tax benefit recognized		305		240		1,151		1,363
Stock-based compensation expense, net of income tax	$	524	$	435	$	2,028	$	2,408

In the thirteen and thirty-nine weeks ended October 28, 2017 and October 29, 2016, we granted the following equity awards:

	Thirteen Weeks Ended				Thirty-Nine Weeks Ended
	October 28, 2017		October 29, 2016		October 28, 2017		October 29, 2016
Stock options		18,577		-		38,949		36,359
Restricted stock unit awards		-		-		108,429		100,775
Performance-based restricted stock unit awards		-		-		54,900		45,300
Deferred stock units		417		588		904		14,744

At October 28, 2017, the total compensation costs related to nonvested restricted stock unit awards not yet recognized was $6.3 million and the weighted-average period over which such awards are expected to be recognized was 2.4 years. The total compensation costs related to nonvested stock options to be recognized was $0.1 million and the period over which the award is expected to be recognized was 0.9 years at October 28, 2017.

Under the 2012 Non-Employee Director Equity Plan (2012 Plan), a total of 3,361 and 2,851 shares of our common stock were awarded during the thirteen and thirty-nine weeks ended October 28, 2017 and October 29, 2016, respectively, as part of the annual equity award to directors in the first quarter.

The weighted-average grant date fair value of stock options granted during the thirteen and thirty-nine weeks ended October 28, 2017 was $4.20 and $6.20 per share, respectively. There were no stock options granted during the thirteen weeks ended October 29, 2016. The weighted-average grant date fair value of stock options granted during the thirty-nine weeks ended October 29, 2016 was $10.56 per share.

Our employee purchases of common stock, the average price per share and the weighted-average grant date fair value of shares purchased through our employee stock purchase plan were as follow:

	Thirteen Weeks Ended				Thirty-Nine Weeks Ended
	October 28, 2017		October 29, 2016		October 28, 2017		October 29, 2016
Shares purchased		6,239		3,236		16,984		11,874
Average price per share	$	12.11	$	29.29	$	18.00	$	27.66
Weighted average fair value at grant date	$	4.52	$	7.25	$	4.43	$	6.94